Literature DB >> 11862332

Kinetic model for the fate of 6-[18F]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function.

David S Goldstein1, Meyer Katzper, Oscar Linares, Irwin J Kopin.   

Abstract

After injection of 6-[18F]fluorodopamine, thoracic positron emission tomographic scanning visualizes the sympathetic innervation of the heart. This report introduces a kinetic model that relates 6-[18F]fluorodopamine positron emission tomographic scanning results to specific aspects of cardiac sympathoneural function. Inputs were the 6-[18F]fluorodopamine concentration in arterial blood and the estimated contribution of circulating metabolites of 6-[18F]fluorodopamine. All of the three compartments in the model were intraneuronal. Two compartments corresponded to vesicles in sympathetic nerves, consistent with the "multiple vesicular pool" hypothesis from preclinical studies. The model successfully fit the empirical time-activity curve for myocardial 6-[18F]fluorodopamine-derived radioactivity and predicted correctly the effects of several neuropharmacological and physiological manipulations on the time-activity curve. Myocardial cell uptake of metabolites of 6-[18F]fluorodopamine from the circulation could explain an immediate peak of 6-[18F]fluorodopamine-derived radioactivity. The model seems useful in predicting effects of altered cardiac sympathetic function on time-activity curves for myocardial 6-[18F]fluorodopamine-derived radioactivity in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862332     DOI: 10.1007/s002100100426

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

2.  Neuronal source of plasma dopamine.

Authors:  David S Goldstein; Courtney Holmes
Journal:  Clin Chem       Date:  2008-09-18       Impact factor: 8.327

3.  Novel electrophilic synthesis of 6-[¹⁸F]fluorodopamine and comprehensive biological evaluation.

Authors:  Olli Eskola; Tove J Grönroos; Alexandru Naum; Päivi Marjamäki; Sarita Forsback; Jörgen Bergman; Sami Länkimäki; Jan Kiss; Timo Savunen; Juhani Knuuti; Merja Haaparanta; Olof Solin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-10       Impact factor: 9.236

4.  Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.

Authors:  David S Goldstein; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

5.  Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases.

Authors:  David S Goldstein; Mark J Pekker; Graeme Eisenhofer; Yehonatan Sharabi
Journal:  JCI Insight       Date:  2019-07-23

6.  Cardiac sympathetic hypo-innervation in familial dysautonomia.

Authors:  David S Goldstein; Basil Eldadah; Yehonatan Sharabi; Felicia B Axelrod
Journal:  Clin Auton Res       Date:  2008-05-22       Impact factor: 4.435

7.  Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Courtney Holmes; Gary W Miller; Shawn Alter; Randy Strong; Deborah C Mash; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2013-07-22       Impact factor: 5.372

8.  Initial Evaluation of AF78: a Rationally Designed Fluorine-18-Labelled PET Radiotracer Targeting Norepinephrine Transporter.

Authors:  Xinyu Chen; Alexander Fritz; Rudolf A Werner; Naoko Nose; Yusuke Yagi; Hiroyuki Kimura; Steven P Rowe; Kazuhiro Koshino; Michael Decker; Takahiro Higuchi
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.